



EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

MINUTES OF THE TEAMS MEETING 16th MARCH 2022

PRESENT:

Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL CCG
Dr S Ramtoola (SR)	Consultant Physician, ELHT (Chairperson)
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Mr J Vaughan (JV)	Senior Medicines Commissioning Pharmacist NHS EL/BwD
Ms Ana Batista (AB)	Medicines Information Pharmacist ELHT
Neil Fletcher (NF)	Director of Pharmacy ELHT
Chris Woods (CW)	Head of Contracting and Costing, Finance
Mr U Akram (UA)	Deputy Lead Pharmacist, LS CFT
Dr T McKenzie (TMc)	GP East Lancashire
Ms F Iqbal (FI)	Senior Pharmacist NHS BwD CCG
Dominic Sebastian (DS)	Consultant Intensivist and Deputy DMD for SAS

IN ATTENDANCE:

Matthew Rostron (MR)	Anaesthetics
Ms L Prince (LP)	Medicines Management Technician, EL CCG
Alistair Gray (AG)	Chief Pharmacy Information Officer

2022/018: APOLOGIES:

None received

2022/019: DECLARATION OF INTEREST

None

2022/020: MINUTES OF FEBRUARY TEAMS MEETING:

February 2022 Minutes Accepted

2022/021: MATTERS ARISING:

2021/147(a,b): Utrogestan® & Topical Oestrogen products – guidance expected in April/May



2021/148: Eosinophilic oesophagitis guidance accepted by ELMMB

2022/006a: Zonisamide liquid: VG has provided a business case for additional capacity within the IMOT service. It was discussed as to whether Zonisamide liquid could be made AMBER traffic light with patients transferring to primary care when their condition is stable. Issues were raised concerning the management of dose changes as the patient gets older. Expected numbers/volume are currently low [approx. 1-2 currently] and the supply chain needs to be in place for GPs.

Action: LR & VG to discuss further and come back to next meeting with a traffic light decision. Deferred to May meeting **Current Traffic Light: RED**

2022/006c: Ethosuximide liquid: Comments as above

Action: Deferred to May meeting.

2022/026: Bedaquiline Funding Request Update: Product has been sent through as an urgent IFR to CSU. VG to check if anything has been received back and AB to follow up progress.

2022/027: BP targets post CVA – Clarity required as to where targets for Primary Care have been sourced as well as the dosing of atorvastatin post CVA. VG to explore information and examples of BP targets and bring to April meeting.

2022/028: Low Calorie Diet Programme and impact on medicines – a national Programme where participants consume 800 calories/day. Concerns raised about monitoring of medicines/dosing whilst on the programme. LR to link with dietetics link at Morecambe Bay, Julie Spencer. Item closed: await further information.

2022/029: Medicines Reconciliation of Red Drugs in Primary Care – A new prescribing system is in development in ELHT – CERNAR, that will go live 12th November 2022. The system will feed information, on discharge, into the GP EMIS system and Pharmacy team. Information will include: the traffic light status [e.g., red drug will be received by primary care as hospital only treatment], unlicensed medication, Homecare products, any chemotherapy treatment

This will be a consolidated medicines reconciliation record that goes to the practice when the outpatient prescription is generated electronically. It will show the source of the medication and flag-up any associated condition prescribed/linked to the drug e.g., Parkinson's disease. The record will also include allergy history, including the reaction: the ACB score. Item Closed.

2022/038a: Inclisiran – The company are currently actively promoting this product with prescribers. Formulary position is GREEN restricted. Further action to be decided when new guidance is available. Item Closed await further guidance.

2022/038c: Request to change meeting starting time to 12:30 - members agreed to keep start time as 12:45pm via MS Teams. Item closed.



2022/043: New Product Request

a. Ampres 10mg/5ml solution for injection (Chloroprocaine hydrochloride)

Requested by anaesthetic department for use in ambulatory day surgery when surgery does not exceed 40 minutes duration. Chloroprocaine hydrochloride has a rapid onset and regression post-surgery of spinal block, less urinary retention, reducing the length of patient stay. Its use will be time saving and improve discharge times.

Action: ELMMB supported the use of Chloroprocaine Hydrochloride
Traffic Light: RED

b. Quattro Multifunctional Solution

c. Ote Clean 40

d. Lens Plus OcuPure Saline

The above items [b.c.d] were requested by Bronagh Clarke, Optometrist at Moorfield Eye Hospital. All the products listed above are available to purchase over the counter and are considered as part of the self-care agenda. It was agreed to move the agenda item to April's meeting and request that the optometrist attend to discuss the request further.

Action: Moved to April agenda and invite to be sent.

2022/044 Formulary Updates

a. Vocabria® [cabotegravir] 600mg/3ml prolonged-release suspension for injection – new HIV injectable drug approved by NICE

Approved for use by ELMMB **Traffic Light: RED**

b. Rekambys® [rilpivirine] -900mg/3ml prolonged-release suspension for injection – new HIV injectable drug approved by NICE.

Approved for use by ELMMB **Traffic Light: RED**

c. Topiramate oral suspension 20mg/mL – requested by paediatrics pharmacist as an addition to the tablets and sprinkle capsules already on formulary. Agreed to add to formulary for use in paediatrics only

Approved for use by ELMMB **Traffic Light: AMBER**

d. Sastravi [Levodopa/ carbidopa/entacapone tablets] – the hospital contract has changed to Sastravi® as the preferred brand. Bioavailability is the same, but members agreed the product should be prescribed and labelled generically to avoid the risk of patient confusion. Supply issues and appearance may also be an issue. An optimise Rx message, Hot Topic will be used to inform practices about the changes.

Approved for use by ELMMB **Traffic Light: AMBER**

e. Xeomin – Current options listed on Formulary are Botox® and Dysport®, request to add Xeomin® as second line option for cases of intolerance to the other two brands.

Approved for use by ELMMB **Traffic Light: RED**



2022/045 LSCMMG Consultations - February 2022

- a. Primary Care PPI Review Pathway: no comments/concerns raised
- b. Ozurdex for diabetic macular oedema, patients not pseudophakic: this has previously been agreed for inclusion in ELHE formulary.
- c. Asthma treatment guidelines for adults [aged 17 years and over]: The guideline has been circulated to respiratory consultants for comment. Previous comments already sent included: the document is long, promotes the use of MART and no SABA included. The inclusion of treatment for acute exacerbations is also required as well as inhaler contents i.e., the drug. The members felt that a desktop document/local guideline would be appropriate.

Action: AB to respond to consultations on behalf of ELHE

2022/046 LSCMMG Recommendations - February 2022

- a. Overactive Bladder in female adults.
- b. Botulinum Toxin Type A for cosmetic procedures - updated entry with resources - Not recommended for prescribing on the NHS in Lancashire & South Cumbria. BLACK Traffic Light [excludes hyperhidrosis]

Resolved: Recommendations acknowledged by ELMMB

2022/047 Other items

FOC Request for Approval - Atezolizumab Neuroendocrine Tumour (AB) - deferred

2022/048 Other items

FOC policy submission for tralokinumab (WP) - deferred

2022/027 Other items

Vit D guidelines: shared with Primary Care and comments have been incorporated. The document promotes the self-care agenda. SR commented that the table within the document needs clarification – high risk patients e.g., with parathyroid disorders, often relapse into deficiency once they achieve the maintenance dose because of having to purchase over the counter.

Action: Guideline to be amended and brought back to May meeting

2022/050 Other items



Eczema guidelines: updated in line with NICE. No combination products are included, and antibiotic courses are 5 days. MicroGuide® has been updated for secondary care to reflect the changes.

ACTION: MicroGuide® for Primary Care will be updated

2022/032 NICE Guidance - February 2022

NG28 Type 2 diabetes in adults, management: updated 15th February 2022

Resolved: item acknowledged by ELMMB

2022/033 NICE Recommendations – February 2022

Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (TA762) Terminated appraisal. **Traffic Light: BLACK**

Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763) Approved in line with NICE
NHS England Commissioned **Traffic Light: RED**

Fremanezumab for preventing migraine (TA764). Approved in line with NICE.
CCG commissioned. Blueteq required. **Traffic Light: RED**

Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable. (TA765). Approved in line with NICE
NHS England Commissioned **Traffic Light: RED**

Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma. (TA766) Approved in line with NICE
NHS England Commissioned **Traffic Light: RED**

Ponesimod for treating relapsing–remitting multiple sclerosis. (TA767).
Approved in line with NICE.
NHS England Commissioned **Traffic Light: RED**

Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs. (TA768) Approved in line with NICE.
CCG commissioned. Blueteq required. **Traffic Light: RED**

Palforzia for treating peanut allergy in children and young people. (TA769)
Approved in line with NICE
CCG commissioned. **Traffic Light: RED**

Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer. (TA770) Approved in line with NICE
NHS England Commissioned **Traffic Light: RED**



Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (TA771). Terminated appraisal) **Traffic Light: BLACK**

Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies. (TA772)

Approved in line with NICE

NHS England Commissioned

Traffic Light: RED

2022/053 NICE Highly Specialised Technologies – February 2022

HST17 Odevixibat for treating progressive familial intrahepatic cholestasis

Resolved: item acknowledged by ELMMB

Standing Items:

2022/054 For Action/Information: Lancashire & South Cumbria Medicines Management Group (LSCMMG)

DRAFT February LSCMMG minutes

Resolved: Minutes acknowledged.

DATE OF NEXT MEETING – Wednesday 20th April 2022 12.45pm via 'Microsoft Teams'

ACTION SHEET FROM EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD



WEDNESDAY 15th March 2022

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2021/101b	ELMMB Membership Chair to send invites to suggested members supplied by AB. LR to look into ELMMB primary care representation and new product request policy to be reviewed and brought back in April	SR LR/VG	Apr 22
2021/147 (a,b)	Utrogestan® & Topical Oestrogen Products – guidance to be put together listing the most cost-effective products options	CM	Apr/May 22
2022/006a	Zonisamide liquid: LR & VG to discuss supply chain and pathway when dose changes are required	VG/LR	May 22
2022/006c	Ethosuximide liquid: LR & VG to discuss further and come back to next meeting [see above]	VG/LR	May 22
2022/026	Bedaquiline Funding request –Vg to check if IFR received AB to follow up progress	VG/AB	Apr 22
2022/027	BP targets post CVA - VG to feedback these concerns to Stroke Physicians and ask them to consider those points and attempt to give a more moderate recommendation. Examples of BP targets also needed. Responses to be brought back to April meeting.	VG	Apr 22
2022/043	Quattro Multifunctional Solution Ote Clean 40 Lens Plus OcuPure Saline AB to send Invite to optometrist to attend April meeting	AB	Apr 22